Breaking News, Collaborations & Alliances

Ethris, Heqet Partner on RNA-based Heart Disease Therapeutics

Heqet to lead program development and Ethris will provide its Stabilized NanoParticle (SNaP) LNP platform to deliver ncRNA payloads.

Ethris GmbH, a biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Heqet Therapeutics, a biotechnology spin-out company from King’s College London active in the field of regenerative medicine, entered into a collaboration agreement to harness the potential of ncRNA for heart tissue regeneration following acute myocardial infarction (heart attack) and in heart failure. Under the terms of the agreement, Heqet Therapeutics will lead the development of the program,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters